There is a 15-minute delay in the prices. To check out the live prices, log in to your Ventura account or open one today.
| Orders | Qty | Bid |
|---|---|---|
| 1 | 25 | 327.9 |
| 1 | 10 | 327.85 |
| 1 | 2 | 327.8 |
| 5 | 40 | 327.75 |
| 5 | 124 | 327.7 |
| Ask | Qty | Orders |
|---|---|---|
| 328.3 | 4 | 119 |
| 328.35 | 1 | 32 |
| 328.4 | 5 | 93 |
| 328.45 | 3 | 109 |
| 328.5 | 3 | 71 |
Our researchers has found no immediate positive insights for this stock. We'll update this space as soon as we find something.
Suven Life Sciences Limited is a clinical-stage biopharmaceutical company focused on acquiring, developing, and commercializing novel therapeutics for neurodegenerative disorders, especially dementia and central nervous system (CNS) indications with high unmet needs and growing patient populations. Incorporated in 1989 and founded by the Jasti Family, the company is based in Hyderabad and listed on BSE and the National Stock Exchange of India Limited. It operates primarily as an R&D-led organization, discovering and developing drugs targeting CNS diseases.
Suven’s pipeline consists of 13 molecules with 5 in clinical trials, among which 3 are in advanced Phase 2 and Phase 3 stages. Lead drugs include Masupirdine (SUVN‑502), Samelisant (SUVN‑G3031), Ropanicant (SUVN‑911), Usmarapride (SUVN‑D4010), and SUVN‑I6107, which address cognitive disorders, schizophrenia, Alzheimer’s disease, sleep-wake disorders, and depressive disorders. The company holds over 2,850 global patents extending up to 2035 and beyond, underscoring a significant intellectual property portfolio.
Suven Life Sciences has geographic coverage across India, the USA, Europe, and other global markets. It operates two research centers in Telangana: IDA Jeedimetla, Hyderabad, and IDA Pashamylaram, Sangareddy, supported by a team of 132 employees, including 102 research scientists.
Suven’s business operates as a single reportable segment centered on R&D and drug development in CNS disorders. Its geographic revenue reporting spans India, the United States, Europe, and other parts of the world.
The company focuses on discovery-led R&D, development, and commercialization of targeted therapeutics for neurodegenerative and CNS diseases. In addition, it provides contract research and manufacturing services (CRAMS) to global pharmaceutical and biotech companies.
The intraday low for Suven Life Sciences Ltd on the NSE today was ₹361.40. The stock's 52-week low stands at ₹124.11, recorded on 24 Mar 2026. Today's low is 191.19% above the 52-week low, indicating the stock is trading well above its yearly lows.
As of 22 Aug 2026, the share price of Suven Life Sciences Ltd is ₹371.90 on the NSE and ₹372.35 on the BSE. The stock opened at ₹377.00, touched a high of ₹389.90 and a low of ₹361.40 during today's session.
Suven Life Sciences Ltd has delivered 61.91% return over the last 52 weeks. During this period, the stock hit a 52-week high of ₹377.45 on 20 Aug 2026 and a 52-week low of ₹124.11 on 24 Mar 2026. It is currently trading at ₹371.90 as of 22 Aug 2026.
Suven Life Sciences Ltd has delivered a 390.35% absolute return over the past 5 years, equivalent to a CAGR of 37.44% per annum. The stock was priced at ₹75.84 in Aug 2021 and has risen to ₹371.90 as of 22 Aug 2026. An investment of ₹1,00,000 in Suven Life Sciences Ltd five years ago would be worth ₹4,90,350.00 today.
The all-time high (ATH) for Suven Life Sciences Ltd was ₹373.60, recorded on 20 Aug 2026. At the current price of ₹371.90, the stock is trading 0.46% below its all-time high. The all-time low recorded was ₹10.69 on 02 Jan 2012.
Over the last 6 months, Suven Life Sciences Ltd has given a return of 147.50%. The stock was priced at ₹150.95 on 23 Feb 2026 and has Rise to ₹371.90 as of 22 Aug 2026, a change of ₹220.95 per share.
No,Suven Life Sciences Ltd has not declared any dividend over the past 5 years. The company paid a total dividend of N/A per share between FY2022 and FY2026, with the most recent dividend of ₹1.50 per share for Jan 19, with an ex-dividend date of 14 Feb 2019. At the current market price of ₹371.90, the trailing dividend yield of Suven Life Sciences Ltd stands at 1.50%.
Suven Life Sciences Ltd has delivered a return of 40.74% over the last 3 months. The stock was trading at ₹265.45 on 22 May 2026 and is currently at ₹371.90 as of 22 Aug 2026, reflecting a Gain of ₹106.45 per share over this period.
The intraday high for Suven Life Sciences Ltd on the NSE today (22 Aug 2026) was ₹389.90. This compares to the 52-week high of ₹377.45 recorded on 20 Aug 2026. Today's high was 3.30% above the 52-week high.
For Q1 FY27, Suven Life Sciences Ltd reported: Revenue (Net Sales): ₹35.65 Cr - Up 134.54% year-on-year from ₹15.20 Cr in Q4 FY26. Net Income (PAT): ₹-161.20 Cr - Down 44.35% year-on-year from ₹-111.67 Cr in Q4 FY26.
